Hepatitis

Hepatitis A

Clinical Manifestations

Assessment/Findings

The liver and spleen are often moderately enlarged for a few days after onset; other than jaundice, there are few other physical signs. Hepatitis A antigen may be found in the stool 7 to 10 days before illness and for 2 to 3 weeks after symptoms appear. HAV antibodies are detectable in the serum, but usually not until symptoms appear. Analysis of subclasses of immunoglobulins can help determine whether the antibody represents acute or past infection.

Medical Management

Bed rest during the acute stage and a diet that is both acceptable to the patient and nutritious are part of the treatment and nursing care. During the period of anorexia, the patient should receive frequent small feedings, supplemented if necessary by IV fluids with glucose. Because the patient often has an aversion to food, gentle persistence and creativity may be required to stimulate appetite. Optimal food and fluid levels are necessary to counteract weight loss and to speed recovery. Even before the icteric phase, however, many patients recover their appetites.The patient’s sense of well-being and laboratory test results are generally appropriate guides to bed rest and restriction of physical activity. Gradual but progressive ambulation seems to hasten recovery, provided the patient rests after activity and does not participate in activities to the point of fatigue

Nursing Management

The nurse assists the patient and family in coping with the temporary disability and fatigue that are common in hepatitis. The patient and family need specific guidelines about diet, rest, follow-up blood work, and the importance of avoiding alcohol, as well as sanitation and hygiene measures (particularly handwashing) to prevent spread of the disease to other family members. Specific teaching to patients and families about reducing the risk of contracting hepatitis A includes good personal hygiene, stressing careful handwashing (after bowel movements and before eating) and environmental sanitation(safe food and water supply, effective sewage disposal).

Many patients are anicteric (without jaundice) and symptomless.


In symptomatic patients:
-low grade fever
-anorexia
-jaundice
-dark urine
-indigestion
-aversion to strong odors

Hepatitis B

Clinical Manifestations

Assessment/Findings

Medical Management

Nursing Management

Clinically, the disease closely resembles hepatitis A, but the incubation period is much longer (1 to 6 months).
Signs and symptoms of hepatitis B may be insidious and variable.


Symptomatic patients:
-arthralgias
-rashes
-loss of appetite
-dyspepsia
-abdominal pain
-generalized aching
-malaise
-weakness

-jaundice
-light-colored stools
-dark urine
-hepatomegaly
-splenomegaly

The goals of treatment are to minimize infectivity and liver inflammation and decrease symptoms.


Of all the agents that have been used to treat chronic type B viral hepatitis, alpha-interferon as the single modality of therapy that offers the most promise.


Two antiviral agents, lamivudine (Epivir) and adefovir(Hepsera), oral nucleoside analogs, have been approved for use in chronic hepatitis B in the United States. Studies have revealed improved seroconversion rates, loss of detectable virus, improved liver function, and reduced progression to cirrhosis with lamivudine. It can be used for patients with decompensated cirrhosis who are awaiting liver transplantation. Adefovir may be effective in people who are resistant to lamivudine.


Bed rest may be recommended, regardless of other treatment, until the symptoms of hepatitis have subsided. Activities are restricted until the hepatic enlargement and levels of serum bilirubin and liver enzymes have decreased.


Adequate nutrition should be maintained. Proteins are restricted if symptoms indicate that the liver’s ability to metabolize protein byproducts is impaired. Measures to control the dyspeptic symptoms and general malaise include the use of antacids and antiemetics, but all medications should be avoided if vomiting occurs.

HBsAg appears in the circulation in 80% to 90% of infected patients 1 to 10 weeks after exposure to HBV and 2 to 8 weeks before the onset of symptoms or an increase intransferase levels. Patients with HBsAg that persists for 6 months or longer after acute infection are considered to beHBsAg carriers. HBeAg is the next antigen of HBV to appear in the serum. It usually appears within 1 week of the appearance of HBsAg but before
changes in aminotransferase levels; it disappears from the serum within 2 weeks. HBV DNA, detected by polymerase chain reaction testing, appears in the serum at about the same time as HBeAg. HBcAg is not always detected in the serum in HBV infection.

Provision for adequate rest and nutrition must be ensured. The nurse informs family members and friends who have had intimate contact with the patient about the risks of contracting hepatitis B and makes arrangements for them to receive hepatitis B vaccine or hepatitis B immune globulin as prescribed.Those at risk must be made aware of the early signs of hepatitis B and of ways to reduce risk by avoiding all modes of transmission. Patients with all forms of hepatitis should avoid drinking alcohol and eating raw shellfish.

Etiology/Pathophysiology

Hepatitis A is caused by an RNA virus of the Enterovirus family. This form of hepatitis is transmitted primarily through the fecal-oral route, by the ingestion of infected foods or liquids. It is more prevalent in countries with overcrowding and poor sanitation. The virus has been found in the stool of infected patients before the onset of symptoms and during the first few days of illness.


The incubation period is estimated to be between 2 to 6 weeks. The illness may be prolonged, lasting 4 to 8 weeks.It usually lasts longer and is more severe in those older than 40 years of age. Most patients recover from hepatitis A; it rarely progresses to acute liver necrosis or fulminant hepatitis resulting in cirrhosis of the liver or death.

Risk Factors

Etiology/Pathophysiology

Frequent exposure to blood, blood products, or other body fluids
Health care workers
•Hemodialysis
Male homosexual and bisexual activity
IV/injection drug use
Close contact with carrier of HBV
•Travel to or residence in area with uncertain sanitary conditions
Multiple sexual partners
•Recent history of sexually transmitted disease
Recipient of blood or blood products

The hepatitis B virus (HBV) is transmitted primarily through blood. HBV can be found in blood, saliva, semen, and vaginal secretions and can be transmitted through mucous membranes and breaks in the skin. HBV is also transferred from carrier mothers to their infants. The infection usually is not transmitted via the umbilical vein but from the mother at the time of birth and during close contact afterward.


HBV has a long incubation period. It replicates in the liver and remains in the serum for relatively long periods, allowing transmission of the virus.

Continuing Care

Follow-up visits by a home care nurse may be needed to assess the patient’s progress and answer family members’ questions about disease transmission.


During a home visit, the nurse assesses the patient’s physical and psychological status and confirms that the patient and family understand the importance of adequate rest and nutrition. The nurse also reinforces previous instructions. Because of the risk of transmission through sexual intercourse, strategies to prevent exchange of body fluids are recommended, such as abstinence or the use of condoms. The nurse emphasizes the importance of keeping follow-up appointments and participating in other health promotion activities and recommended health screenings.

Hepatitis C

Management

There is no benefit from rest, diet, or vitamin supplements. Studies have demonstrated that a combination of two antiviral agents, interferon (Intron-A) and ribavirin(Rebetol), is effective in producing improvement in patients with hepatitis C and in treating relapses. Some patients experience complete remission with combination therapy. Hemolytic anemia, the most frequent side effect, may be severe enough to require discontinuation of treatment. Ribavirin must be used with caution in women of childbearing age.

Risk Factors

Etiology/Pathophysiology

Recipient of blood products or organ transplant before1992 or clotting factor concentrates before 1987
Health care and public safety workers after needlestick injuries or mucosal exposure to blood
Children born to women infected with hepatitis C virus
•Past/current illicit IV/injection drug use
•Past treatment with chronic hemodialysis
Multiple sex partners, history of sexually transmitted disease, unprotected sex

The incubation period is variable and may range from 15 to 160 days. The clinical course of acute hepatitis C is similar to that of hepatitis B. Chronic carrier state occurs frequently, and there is an increased risk of chronic liver disease, including cirrhosis or liver cancer, after hepatitis C. Small amounts of alcohol taken regularly appear to cause progression of the disease. Therefore, alcohol and medications that may affect the liver should be avoided.

Hepatitis D

Risk Factors

Assessment/Findings

Etiology

Clinical Manifestations

Management

Hepatitis D virus (delta agent) infection occurs in some cases of hepatitis B.
The incubation period varies between 30 and 150 days

Because the virus requires hepatitis B surface antigen for its replication, only people with hepatitis B are at risk for hepatitis D.
Hepatitis D is common among IV or injection drug users, hemodialysis patients, and recipients of multiple blood transfusions. Sexual contact with those with hepatitis B is considered to be an important mode of transmission of hepatitis B and D.

Anti-delta antibodies in the presence of HBAg on testing confirm the diagnosis.

The symptoms of hepatitis D are similar to those of hepatitis B, except that patients are more likely to develop fulminant hepatitis and to progress to chronic active hepatitis and cirrhosis.

Treatment is similar to that of other forms of hepatitis; interferon as a specific treatment for hepatitis D is under investigation

Hepatits E

It is believed that hepatitis E virus (HEV) is transmitted by the fecal-oral route, principally through contaminated water in areas with poor sanitation.


The incubation period is variable, estimated to range between 15 and 65 days.


In general, hepatitis E resembles hepatitis A. It has a self-limited course with an abrupt onset.


Jaundice is almost always present.


Chronic forms do not develop.


Avoiding contact with the virus through good hygiene, including handwashing, is the major method of prevention of hepatitis E.


The effectiveness of immune globulin in protecting against hepatitis E virus is uncertain.